169 related articles for article (PubMed ID: 10593699)
21. In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders.
Stanley JA
Can J Psychiatry; 2002 May; 47(4):315-26. PubMed ID: 12025430
[TBL] [Abstract][Full Text] [Related]
22. A review of 1H MR spectroscopy findings in Alzheimer's disease.
Soher BJ; Doraiswamy PM; Charles HC
Neuroimaging Clin N Am; 2005 Nov; 15(4):847-52, xi. PubMed ID: 16443495
[TBL] [Abstract][Full Text] [Related]
23. Neuroimaging as a probe of brain function in late-life psychiatric illness: old paradigms, new challenges.
Kumar A
J Geriatr Psychiatry Neurol; 1999; 12(3):93-4. PubMed ID: 10593697
[No Abstract] [Full Text] [Related]
24. Serial structural MRI analysis and proton and 31PMR spectroscopy in the investigation of cerebral fatty acids in major depressive disorder, Huntington's disease, myalgic encephalomyelitis and in forensic schizophrenic patients.
Puri BK; Tsaluchidu S; Treasaden IH
World Rev Nutr Diet; 2009; 99():31-45. PubMed ID: 19136837
[No Abstract] [Full Text] [Related]
25. Cerebral blood flow and metabolism in late-life depression and dementia.
Nobler MS; Pelton GH; Sackeim HA
J Geriatr Psychiatry Neurol; 1999; 12(3):118-27. PubMed ID: 10593700
[TBL] [Abstract][Full Text] [Related]
26. Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice.
Waragai M; Hata S; Suzuki T; Ishii R; Fujii C; Tokuda T; Arai H; Ohrui T; Higuchi S; Yoshida M; Igarashi K; Moriya M; Iwai N; Uemura K
J Alzheimers Dis; 2014; 41(4):1207-22. PubMed ID: 24787913
[TBL] [Abstract][Full Text] [Related]
27. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
[TBL] [Abstract][Full Text] [Related]
28. Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Pilatus U; Lais C; Rochmont Adu M; Kratzsch T; Frölich L; Maurer K; Zanella FE; Lanfermann H; Pantel J
Psychiatry Res; 2009 Jul; 173(1):1-7. PubMed ID: 19427767
[TBL] [Abstract][Full Text] [Related]
29. NMR spectroscopic evaluation of cerebral metabolism in hydrocephalus: a review.
Braun KP; Vandertop WP; Gooskens RH; Tulleken KA; Nicolay K
Neurol Res; 2000 Jan; 22(1):51-64. PubMed ID: 10672581
[TBL] [Abstract][Full Text] [Related]
30. Proton Magnetic Resonance Spectroscopy in Common Dementias-Current Status and Perspectives.
Maul S; Giegling I; Rujescu D
Front Psychiatry; 2020; 11():769. PubMed ID: 32848938
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy.
Nicoli F; Vion-Dury J; Confort-Gouny S; Maillet S; Gastaut JL; Cozzone PJ
C R Acad Sci III; 1996 Jul; 319(7):623-31. PubMed ID: 9011324
[TBL] [Abstract][Full Text] [Related]
32. Brain choline in major depression: A review of the literature.
Riley CA; Renshaw PF
Psychiatry Res Neuroimaging; 2018 Jan; 271():142-153. PubMed ID: 29174766
[TBL] [Abstract][Full Text] [Related]
33. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Pina MA
Am J Psychiatry; 2005 Apr; 162(4):667-75. PubMed ID: 15800137
[TBL] [Abstract][Full Text] [Related]
34. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders.
Chang L; Cloak CC; Ernst T
J Clin Psychiatry; 2003; 64 Suppl 3():7-14. PubMed ID: 12662128
[TBL] [Abstract][Full Text] [Related]
35. Correlation of findings in advanced MR techniques with global severity scales in patients with some grade of cognitive impairment.
Fayed N; Dávila J; Oliveros A; Medrano J; Castillo J
Neurol Res; 2010 Mar; 32(2):157-65. PubMed ID: 20158954
[TBL] [Abstract][Full Text] [Related]
36. Localized proton and phosphorus magnetic resonance spectroscopy following electroconvulsive therapy.
Felber SR; Pycha R; Hummer M; Aichner FT; Fleischhacker WW
Biol Psychiatry; 1993 Apr 15-May 1; 33(8-9):651-4. PubMed ID: 8392387
[TBL] [Abstract][Full Text] [Related]
37. Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease.
Pagonabarraga J; Gómez-Ansón B; Rotger R; Llebaria G; García-Sánchez C; Pascual-Sedano B; Gironell A; Delfino M; Ruscalleda J; Kulisevsky J
Dement Geriatr Cogn Disord; 2012; 34(5-6):312-8. PubMed ID: 23208306
[TBL] [Abstract][Full Text] [Related]
38. From fetus to older age: A review of brain metabolic changes across the lifespan.
Cichocka M; Bereś A
Ageing Res Rev; 2018 Sep; 46():60-73. PubMed ID: 29864489
[TBL] [Abstract][Full Text] [Related]
39. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy?
Vion-Dury J; Meyerhoff DJ; Cozzone PJ; Weiner MW
J Neurol; 1994 May; 241(6):354-71. PubMed ID: 7931430
[TBL] [Abstract][Full Text] [Related]
40. 1H magnetic resonance spectroscopy in multiple sclerosis and related disorders.
Rovira A; Alonso J
Neuroimaging Clin N Am; 2013 Aug; 23(3):459-74. PubMed ID: 23928200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
